Literature DB >> 7076644

The occurrence of GM4 and GM2 in erythrocytes from inbred strains of mice.

Y Hashimoto, H Otsuka, T Yamakawa.   

Abstract

Glycolipids of erythrocytes from inbred mice, C3H/He and CDF1, were analyzed. Galactosylceramide, glucosylceramide, GM4 and GM2 were separated and their structures were established. Sialic acid of GM4 was exclusively N-acetylneuraminic acid, while GM2 contained only N-glycolylneuraminic acid. The fatty acid composition of GM4 was very similar to that of galactosylceramide, and a similarity was also found between that of GM2 and glucosylceramide. These results suggest that erythroid cells of mice have two separate biosynthetic pathways of gangliosides. One is the pathway to GM4 (NeuAc) from galactosylceramide, and the other is that for synthesizing GM2 (NeuGc) from glucosylceramide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076644     DOI: 10.1093/oxfordjournals.jbchem.a133753

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  3 in total

1.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.

Authors:  Dan Wang; Valery Belakhov; Jeyakumar Kandasamy; Timor Baasov; Su-Chen Li; Yu-Teh Li; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

2.  Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.

Authors:  P O Livingston; G Ritter; M J Calves
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Metabolism of vertebrate amino sugars with N-glycolyl groups: resistance of α2-8-linked N-glycolylneuraminic acid to enzymatic cleavage.

Authors:  Leela R L Davies; Oliver M T Pearce; Matthew B Tessier; Siavash Assar; Victoria Smutova; Maria Pajunen; Mizuki Sumida; Chihiro Sato; Ken Kitajima; Jukka Finne; Pascal Gagneux; Alexey Pshezhetsky; Robert Woods; Ajit Varki
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.